Β3-Adrenergic Receptors and Prematurity-Related Diseases: A Systematic Review
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Beta3 adrenergic receptors (β3-ARs) are upregulated in hypoxia and may play a role in fetal development and preterm infant diseases. Their activation offers protective effects, but altered expression in preterm infants could contribute to pathologies.
Area Of Science
- Perinatal Medicine
- Molecular Biology
- Developmental Biology
Background
- Beta3 adrenergic receptors (β3-ARs) exhibit broad tissue expression and diverse functions.
- Emerging research suggests β3-ARs involvement in common preterm infant complications.
- This systematic review investigates the role of β3-ARs in fetal development and neonatal diseases.
Purpose Of The Study
- To systematically review the scientific literature on the association between β3-ARs, fetal development, and diseases in preterm newborns.
Main Methods
- Searched PubMed/Medline and Cochrane databases for relevant studies.
- Included studies reporting associations between β3-ARs, fetal development, and preterm infant diseases.
- Selected 16 studies from an initial pool of 1596 articles for the review.
Main Results
- β3-ARs are upregulated in hypoxic conditions across multiple tissues.
- Activation of β3-ARs promotes pro-angiogenic, anti-inflammatory, immunoregulatory, and metabolic adaptation effects.
- These effects are crucial for normal fetal development.
Conclusions
- Preclinical data indicate a potential role for β3-ARs in the pathogenesis of numerous preterm newborn pathologies.
- Preterm birth disrupts the natural hypoxic fetal environment, exposing infants to relative hyperoxia.
- Altered β3-AR expression and activity due to premature oxygen exposure may impair fetal development and cause organ injury.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
Sympathetic signaling, a vital part of the autonomic nervous system, plays a crucial role in mobilizing the body's resources in response to stress or emergencies. It involves the transmission of nerve impulses from sympathetic preganglionic fibers to postganglionic fibers. This results in the release of specific neurotransmitters and activation of adrenergic receptors.
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...